Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 35,419 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Insomnia, Nightmares, Posttraumatic Stress Disorder
Interventions: Cognitive-Behavioral Insomnia and Nightmare Group; Behavioral
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Sinusitis, Polyposis
Interventions: pulmicort; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Stroke, Acute Ischemic Stroke
Interventions: NovaGuide 2 Intelligent Ultrasound System; Device
Lead sponsor: NeuraSignal Inc dba NovaSignal; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Healthy Participants
Interventions: Plixorafenib, Cobicistat; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Vulvovaginitis, Vaginitis
Interventions: clindamycin phosphate/butoconazole nitrate, clindamycin phosphate, butoconazole nitrate; Drug
Lead sponsor: Lumara Health, Inc.; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 1,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 81
States / cities: Birmingham, Alabama • Enterprise, Alabama • Chandler, Arizona + 69 more

Conditions: Wellness, Health
Interventions: Ubiquinol + geranylgeraniol, Geranylgeraniol, Ubiquinol, Ubiquinone, Placebo; Dietary Supplement · Other
Lead sponsor: OvationLab; Network
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: El Dorado Hills, California • Centennial, Colorado • Palm Springs, Florida + 3 more

Conditions: Healthy
Interventions: Metronidazole + MMX Mesalazine/mesalamine placebo, Metronidazole + MMX Mesalazine/mesalamine; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Gastric Procedures, Lung Resection Procedures
Interventions: Staple Line Reinforcement; Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Indianapolis, Indiana • Baton Rouge, Louisiana • Detroit, Michigan + 5 more

Conditions: Nicotine Dependence
Interventions: Text messaging prior to first counseling call, Text-to-Enhance, Mail Notice, Telephone Counseling; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: San Diego, California • New York, New York

Conditions: Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma
Interventions: Enzalutamide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Neuromuscular Blockade
Interventions: Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Day to 2 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more

Conditions: Bladder Cancer
Interventions: cisplatin, 5-fluorouracil, Mitomycin, Three-Dimensional Conformal Radiation Therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 13
States / cities: Atlanta, Georgia • Baltimore, Maryland • Fall River, Massachusetts + 9 more

Conditions: Vitamin D Deficiency, Hypertension
Interventions: Aliskiren, Cholecalciferol, Placebo; Drug · Dietary Supplement
Lead sponsor: UConn Health; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Hematologic Malignancies
Interventions: SLS009, venetoclax, azacitidine; Drug
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: PF-02341066; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,069 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 140
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 71 more

Conditions: Severe Traumatic Brain Injury
Interventions: Conivaptan (Vaprisol); Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy, Endocrine System Diseases, Orbital Diseases, Proptosis, Eye Diseases
Interventions: LASN01, Placebo; Drug
Lead sponsor: Lassen Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Beverly Hills, California • Palo Alto, California • San Diego, California + 6 more

Conditions: Paracentesis
Interventions: HoloUS app for ultrasound visualization; Device
Lead sponsor: Children's National Research Institute; Other
Eligibility: 18 Years to 100 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Glioblastoma Multiforme
Interventions: VBI-1901, Carmustine, Lomustine; Biological · Drug
Lead sponsor: VBI Vaccines Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 12
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 8 more

Conditions: Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Interventions: glecaprevir/pibrentasvir (GLE/PIB); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Chronic Pelvic Pain
Interventions: Empowered Relief (ER) Therapy; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections
Interventions: CMV-specific T-cells; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 1 Month and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Postpartum Depression
Interventions: Estradiol, Placebo, Progesterone, leuprolide acetate; Drug · Other
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Smoking
Interventions: mTHS 2.2, mCC, NNS; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Initial Study of Insomnia/Nightmare Group Treatment for Posttraumatic Stress Disorder (PTSD)

Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis

Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

Vaginal Infection Study

Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations

Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine

Study of ECHELON ENDOPATH(TM) Staple Line Reinforcement

Text Messaging to Engage and Retain Veterans in Smoking Cessation Counseling

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Vitamin D Deficiency in Patients With Hypertension

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Augmented Reality Ultrasound Guidance

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

Empowered Relief for Chronic Pelvic Pain

Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells

The Role of Hormones in Postpartum Mood Disorders

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)